|
|
|
|
| LEADER |
04878nmm a2200313 u 4500 |
| 001 |
EB000285905 |
| 003 |
EBX01000000000000000050140 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
090727 ||| eng |
| 020 |
|
|
|a 9781592593347
|
| 050 |
|
4 |
|a RC254-282
|
| 100 |
1 |
|
|a Welschof, Martin
|e [editor]
|
| 245 |
0 |
0 |
|a Recombinant Antibodies for Cancer Therapy
|h Elektronische Ressource
|b Methods and Protocols
|c edited by Martin Welschof, Jürgen Krauss
|
| 250 |
|
|
|a 1st ed. 2003
|
| 260 |
|
|
|a Totowa, NJ
|b Humana Press
|c 2003, 2003
|
| 300 |
|
|
|a XIV, 481 p
|b online resource
|
| 505 |
0 |
|
|a Single-Chain Fv-Based Affinity Purification of the Cellular Stress Protein gp96 for Vaccine Development -- Recombinant Adenoviruses for In Vivo Expression of Antibody Fragments -- Large Scale Production of Recombinant Antibodies for Clinical Application -- Production of Antibody Fragments in a Bioreactor -- Large Scale Production of Recombinant Antibodies by Utilizing Cellulose-Binding Domains -- Production of Tumor-Specific Antibodies in Tobacco
|
| 505 |
0 |
|
|a Generation of Antibody Molecules Through Antibody Engineering -- Application of Recombinant Antibodies in Cancer Patients -- Hybridoma-Derived Antibodies -- DNA Immunization as a Means to Generate Antibodies to Proteins -- Chimerization of a Monoclonal Antibody for Treating Hodgkin's Lymphoma -- Humanization of Monoclonal Antibodies by CDR Grafting -- Recombinant Antibody Fragments from Phagemid-Displayed Antibody Repertoires -- Generation and Screening of a Modular Human scFv Expression Library from Multiple Donors -- Construction of Semisynthetic Antibody Libraries -- Single-Domain VH Antibody Fragments from a Phage Display Library -- Isolation of Human Fab Fragments Against Ovarian Carcinoma Using Guided Selection -- Human Recombinant Fab Antibodies with T-Cell Receptor-Like Specificities Generated from Phage Display Libraries -- Engineering Hot Spots for Affinity Enhancement of Antibodies -- Simultaneous Humanization and Affinity Optimization of Monoclonal Antibodies --
|
| 505 |
0 |
|
|a Tailoring Kinetics of Antibodies Using Focused Combinatorial Libraries -- Antibody Fragments with Additional Properties -- Engineering scFvs for Improved Stability -- Recombinant Single-Chain and Disulfide-Stabilized Fv Immunotoxins for Cancer Therapy -- Generation of Recombinant Immunotoxins for Specific Targeting of Tumor-Related Peptides Presented by MHC Molecules -- Construction and Characterization of RNase-Based Targeted Therapeutics -- Bispecific Diabodies for Cancer Therapy -- Generation and Characterization of Bispecific Tandem Diabodies for Tumor Therapy -- Generation of Recombinant Multimeric Antibody Fragments for Tumor Diagnosis and Therapy -- Construction and Characterization of Minibodies for Imaging and Therapy of Colorectal Carcinomas -- Generation, Expression, and Monitoring of Recombinant Immune Receptors for Use in Cellular Immunotherapy -- Tailoring Natural Effector Functions --
|
| 653 |
|
|
|a Oncology
|
| 700 |
1 |
|
|a Krauss, Jürgen
|e [editor]
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b SPRPROT
|a Springer Protocols Archive 1981-2004
|
| 490 |
0 |
|
|a Methods in Molecular Biology
|
| 028 |
5 |
0 |
|a 10.1385/1592593348
|
| 856 |
4 |
0 |
|u https://doi.org/10.1385/1592593348?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 616.994
|
| 520 |
|
|
|a Many antibodies recently developed as therapeutic agents have been tailored by the powerful new recombinant antibody technology, and already their clinical data show highly encouraging results. In Recombinant Antibodies for Cancer Therapy: Methods and Protocols, Martin Welschof and Jürgen Krauss present a collection of carefully selected protocols for the design, construction, and characterization of those novel anticancer therapeutics. Written by seasoned investigators who have successfully verified the particular method described, these readily reproducible methods include coverage of hybridoma-derived recombinant antibodies, recombinant antibody fragments from phagemid-displayed antibody repertoires, antibody fragments with additional properties, and large-scale production of recombinant antibodies for clinical applications. The main focus is on providing detailed protocols that describe these procedures step-by-step, accompanied by a troubleshooting guide discussing possible problems and offering many tips for their potential solutions. Concise review articles also survey the current status of recombinant antibodies in cancer therapy, as well as the generation of antibody molecules through antibody engineering. Up-to-date and highly practical, Recombinant Antibodies for Cancer Therapy: Methods and Protocols surveys the current status of engineered antibodies and describes in rich detail many readily reproducible methods of generating the novel and promising antibody-based reagents of today's cancer therapy
|